QO IIR is a reversible, tight-binding inhibitor inhibitor of catechol-O-methyltransferase (COMT) with IC50 of 320 nM.

QM385 is a highly potent small molecule SPR inhibitor,that inhibits the BH4 pathway, blocking T cell proliferation and autoimmunity.

QM31 (SVT016426, Apaf-1 inhibitor QM31) is a cytoprotective agent that inhibits the formation of the apoptosome (IC50=7.9 uM in vitro), the caspase activation complex composed by Apaf-1, cytochrome c, dATP and caspase-9.

QL-X-138 is a selective and potent BTK/MNK dual kinase inhibitor with IC50 of 8, 107.4, and 26 nM for BTK, MNK1, and MNK2, respectively.

QL-IX-55 is a selective ATP-competitive inhibitor of mTORC1/2 with IC50s of 50/50/10-50 nM for Human mTORC1/Yeast mTORC1/Yeast mTORC2, respectively

QD325 is a potent redox modulator that induces Nrf2-mediated oxidative stress and unfolded protein responses in PDAC cells (IC50=0.9 uM).

QD 232 is a novel quinazolinedione-based redox modulator that potently inhibits Src/FAK and STAT3 phosphorylation, decreasing pancreatic cancer cell viability and migration.

QCA570 is a novel, highly potent efficacious BET degrader (PROTAC).

QC-6352 is a potent and selective KDM4 family inhibitor with IC50 of 104, 56, 35, and 104 nM for KDM4A, KDM4B, KDM4C, and KDM4D, respectively.

Q151 is a highly potent inhibitor of mycobacterium tuberculosis IMPDH2 (MtbIMPDH2) with Kiapp of 18 nM, demonstrates the minimum inhibitory concentrations (MIC) of 1 uM withour significant cytotoxicity.

PYZD-4409 is a novel small molecule inhibitor of Ubiquitin-activating enzyme UBA1/E1 enzyme with an IC50 of 20 uM (cell-free enzymatic assay).

Pyrrophenone is a potent cPLA2α inhibitor with enzyme IC50 of 4.2 nM.

Pyrimidyn 7 is a potent, dual-action dynamin GTPase activity inhibitor with IC50 of 1.1 uM/1.8 uM for dynamin I/dynamin II respectively, competitively inhibits both GTP and phospholipid interactions with dynamin.

Pyrimidinone 8 is a novel allosteric, non-competitive divalent metal transporter-1 (SLC11A2/DMT1) inhibitor with Ki of 20 uM.

Pyrazinib (Pyrazinib (P3)) is a pyrazine phenol small molecule drug with anti-angiogenic and anti-metabolic activity in-vivo in zebrafish and in-vitro isogenic models of OAC radioresistance.

Pyr6 is a selective inhibitor of TRPC3 with IC50 of 0.49 uM(Ca2+ influx inhibition in thapsigargin depleted native RBL-2H3 cells).

PyP-1 is a potent, highly selective, and orally bioavailable PDE10A inhibitor with Ki of 0.23 nM.

Pyk2-IN-25a is a highly potent Pyk2 (PTK2B) inhibitor with IC50 of 0.67 nM, dispalys 2-fold weakening potency for FAK (IC50=1.26 nM).

PX20606, also known as PX-102, is a FXR agonist.

PWZ-029 is a potent, subtype-selective partial inverse agonist of α5 GABAA receptors with Ki of 30 nM, demonstrates memory enhancing effects in vivo.

PVZB-1194 is a bis(hetero)aryl derivative that inhibits kinesin spindle protein (KSP) ATPase witn IC50 of 0.12 uM.

Pulsatilla saponin D(SB365) isolated from the root of Pulsatilla koreana, has exhibited potential beneficial effects as a chemopreventive agent for critical health conditions including cancer.

Pulchinenoside A is a natural triterpenoid saponin that enhances synaptic plasticity in the adult mouse hippocampus and facilitates spatial memory in adult mice.

PU-141 is a potent, selective CBP/p300 inhibitor that inhibits SK-N-SH cell growth with GI50 of 0.48 uM.

PU-139 is a potent, unselective HAT (Histone acetyltransferase) inhibitor that blocks the HATs Gcn5, p300/CBP-associated factor (PCAF), CREB protein (CBP) and p300.

PTUPB is a novel dual acting COX-2/sEH inhibitor with IC50 of 1.26 uM/0.9 nM,does not inhibits COX-1 (IC50>100 uM).

PTP1B-IN-5b is a potent protein tyrosine phosphatase PTP1B inhibitor with IC50 of 5.25 uM.

PTGR2-IN-22 is a potent PTGR2 ligand that inhibits 15-keto-PGE2 reductase activity with IC50 of 0.55 uM in HEK293T cells.

Pterosin B is a potent and specific SIK3 signaling inhibitor that suppresses SIK3 downstream cascades by up-regulating the phosphorylation levels in the SIK3 C-terminal regulatory domain.

PTC725 is a potent, selective, and orally bioavailable inhibitor of HCV NS4B, inhibits HCV 1b (Con1) replicons with EC50 of 1.7 nM.